Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Assembly Biosciences (ASMB)
NASDAQ:ASMB
Assembly Biosciences (ASMB) Stock Price & Analysis
514 Followers
ASMB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.69 - $20.04
Previous Close$15.13
Volume12.27K
Average Volume (3M)17.21K
Market Cap
$93.29M
Enterprise Value-$17.75M
Total Cash (Recent Filing)$112.98M
Total Debt (Recent Filing)$1.94M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Aug 07, 2024EPS Estimate
-$2.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.83
Shares Outstanding5,513,308
10 Day Avg. Volume18,432
30 Day Avg. Volume17,206
Standard Deviation0.19
R-Squared0.03
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)2.07
Price to Sales (P/S)563.58
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-3.07
Enterprise Value/Gross Profit-116.00
Enterprise Value/Ebitda0.29
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Assembly Biosciences News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsA Phase 1b study of ABI-4334 in HBV patients is on target to initiate by mid-year 2024, with interim data expected by year-end 2024.
Drug DevelopmentABI-5366 has shown nanomolar potency against both HSV type 1 (HSV-1) and HSV type 2 (HSV-2) in-vitro, and importantly showed sustained plasma concentrations for over 30 days given either orally or subcutaneously in preclinical studies, thus supporting its potential as a long-acting therapeutic.
Financial PerformanceTwo equity financings adding $12.6M of gross proceeds.
Bears Say
Financial PerformancePreviously removed price target for ASMB shares as the valuation was based on the projected revenue from its HBV core inhibitor program.
Operational RisksKey risks include failed or equivocal trial results, unforeseen safety or tolerability issues, meaningful delays to expected timelines, and inability to sufficiently fund operations.
Safety And EfficacyCurrently uncertain on the safety and efficacy of Assembly's programs including ABI-5366 and ABI-6250.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ASMB FAQ
What was Assembly Biosciences’s price range in the past 12 months?
Assembly Biosciences lowest stock price was $7.69 and its highest was $20.04 in the past 12 months.
What is Assembly Biosciences’s market cap?
Currently, no data Available
When is Assembly Biosciences’s upcoming earnings report date?
Assembly Biosciences’s upcoming earnings report date is Aug 07, 2024 which is in 15 days.
How were Assembly Biosciences’s earnings last quarter?
Assembly Biosciences released its earnings results on May 08, 2024. The company reported -$1.66 earnings per share for the quarter, beating the consensus estimate of -$3.23 by $1.57.
Is Assembly Biosciences overvalued?
According to Wall Street analysts Assembly Biosciences’s price is currently Overvalued.
Does Assembly Biosciences pay dividends?
Assembly Biosciences does not currently pay dividends.
What is Assembly Biosciences’s EPS estimate?
Assembly Biosciences’s EPS estimate is -$2.23.
How many shares outstanding does Assembly Biosciences have?
Assembly Biosciences has 6,166,061 shares outstanding.
What happened to Assembly Biosciences’s price movement after its last earnings report?
Assembly Biosciences reported an EPS of -$1.66 in its last earnings report, beating expectations of -$3.23. Following the earnings report the stock price went up 1.245%.
Which hedge fund is a major shareholder of Assembly Biosciences?
Among the largest hedge funds holding Assembly Biosciences’s share is Platinum Investment Management. It holds Assembly Biosciences’s shares valued at N/A.
---
Assembly Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Hedge Fund Trend
Decreased
By 74.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $41.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.58%
12-Months-Change
Fundamentals
Return on Equity
-99.78%
Trailing 12-Months
Asset Growth
44.24%
Trailing 12-Months
Company Description
Assembly Biosciences
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin on October 7, 2005 and is headquartered in Carmel, IN.
---
ASMB Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Adverum Biotechnologies
―
ACADIA Pharmaceuticals
―
Arcturus Therapeutics
―
Axsome Therapeutics
―
Best Analysts Covering ASMB
1 Year
1 Year Success Rate
4/27 ratings generated profit
1 Year Average Return
-40.87%
reiterated a buy rating 4 months ago
Copying Salim Syed's trades and holding each position for 1 Year would result in 14.81% of your transactions generating a profit, with an average return of -40.87% per trade.
---